TokenPost topic
2 TokenPost stories are tagged Clinical trial. The newest appear first.
The confirmed responses came in 10 of 18 evaluable patients with metastatic non-small cell lung cancer treated after chemotherapy and immunotherapy.
Oct 25, 2026, 3:21 PM EDT · Business
Median overall survival was 14.9 months with ivonescimab and chemotherapy, versus 12.1 months with durvalumab and chemotherapy in the late-stage trial conducted in China.
Oct 25, 2026, 2:41 PM EDT · Business